{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:03:12Z","timestamp":1794016992599,"version":"4.8.0"},"reference-count":80,"publisher":"American Association for Cancer Research (AACR)","issue":"11","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA236734"],"award-info":[{"award-number":["T32CA236734"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5K12CA086913-21"],"award-info":[{"award-number":["5K12CA086913-21"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","award":["Career Development Award"],"award-info":[{"award-number":["Career Development Award"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA046934"],"award-info":[{"award-number":["P30CA046934"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>In this preclinical human immune system patient-derived xenograft (HIS-PDX) model and phase II clinical trial, we assessed evorpacept (anti-CD47 engineered fusion protein with inactive Fc), cetuximab, and pembrolizumab (triple therapy) in microsatellite-stable (MSS) colorectal cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>HIS BALB\/c-Rag2nullIl2r\u03b3nullSirp\u03b1NOD mice with PDXs were treated with triple therapy or its components. Patients with refractory MSS colorectal cancer were treated with triple therapy in a safety run-in (stage 1) followed by expansion (stage 2, planned N = 42). The co-primary objectives were to determine the recommended dose of evorpacept and objective response rate (vs. historic control).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In HIS-PDX mice, triple therapy decreased the growth of MSS colorectal cancer tumors and increased tumor-infiltrating CD8+ T cells. Sixteen patients were treated on the clinical trial across two evorpacept dose levels: N = 12 in stage 1 and N = 4 in stage 2. Trial enrollment was terminated early because of safety concerns (one treatment-related grade 5 event each of hemophagocytic lymphohistiocytosis and cytokine release syndrome). Otherwise, the adverse event profile was as expected. Among all patients, the objective response rate was 6.3%; formal hypothesis testing was not performed. The disease control rate was 12.5%, the median progression-free survival was 2.3 months, and the median overall survival was 10.9 months. Blood- and tumor-based clinical trial correlative analyses identified innate and adaptive immune system activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Whereas triple therapy demonstrated evidence of efficacy in refractory MSS colorectal cancer, safety concerns halted enrollment. Further investigation is necessary to determine the optimal use of CD47-targeted therapies in MSS colorectal cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Evorpacept, cetuximab, and pembrolizumab demonstrated antitumor activity in a preclinical HIS-PDX model and clinical trial in refractory MSS colorectal cancer; however, immune-related adverse events prompted early termination of study enrollment. Evidence of innate and adaptive antitumor immune activation was identified. The role of SIRP\u03b1\/CD47 blockade in the treatment of MSS colorectal cancer needs to be further elucidated in future trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0332","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:51:04Z","timestamp":1761922264000},"page":"2039-2052","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7207-8195","authenticated-orcid":false,"given":"Robert W.","family":"Lentz","sequence":"first","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2424-8222","authenticated-orcid":false,"given":"Julie","family":"Lang","sequence":"additional","affiliation":[{"name":"2Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8123-9894","authenticated-orcid":false,"given":"Todd M.","family":"Pitts","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-7263","authenticated-orcid":false,"given":"Patrick","family":"Blatchford","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5937-7916","authenticated-orcid":false,"given":"Junxiao","family":"Hu","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8380-7157","authenticated-orcid":false,"given":"Kimberly R.","family":"Jordan","sequence":"additional","affiliation":[{"name":"2Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6059-2429","authenticated-orcid":false,"given":"Adrie","family":"Van Bokhoven","sequence":"additional","affiliation":[{"name":"4Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3355-3861","authenticated-orcid":false,"given":"Stacey M.","family":"Bagby","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-7805","authenticated-orcid":false,"given":"Adrian T.A.","family":"Dominguez","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0529-5930","authenticated-orcid":false,"given":"Cameron A.","family":"Binns","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9150-8015","authenticated-orcid":false,"given":"Hannah R.","family":"Robinson","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5223-5440","authenticated-orcid":false,"given":"Nicole","family":"Balmaceda","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7262-6078","authenticated-orcid":false,"given":"Emily","family":"Baiyee","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0652-8151","authenticated-orcid":false,"given":"Alexis D.","family":"Leal","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3871-5112","authenticated-orcid":false,"given":"Sunnie S.","family":"Kim","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-9481","authenticated-orcid":false,"given":"S. Lindsey","family":"Davis","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4852-4642","authenticated-orcid":false,"given":"Christopher H.","family":"Lieu","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1959-5406","authenticated-orcid":false,"given":"Raymond C.","family":"Wadlow","sequence":"additional","affiliation":[{"name":"5Inova Schar Cancer Institute, Fairfax, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5577-3439","authenticated-orcid":false,"given":"Kristen","family":"Spencer","sequence":"additional","affiliation":[{"name":"6Perlmutter Cancer Center of NYU Langone Health and NYU Grossman School of Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0301-3072","authenticated-orcid":false,"given":"Aaron J.","family":"Scott","sequence":"additional","affiliation":[{"name":"7Division of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Arizona Cancer Center, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4213-8847","authenticated-orcid":false,"given":"Patrick M.","family":"Boland","sequence":"additional","affiliation":[{"name":"8Division of Medical Oncology, Department of Medicine, Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-1529","authenticated-orcid":false,"given":"Howard S.","family":"Hochster","sequence":"additional","affiliation":[{"name":"8Division of Medical Oncology, Department of Medicine, Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2349-0885","authenticated-orcid":false,"given":"Wells A.","family":"Messersmith","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2025112002023041900_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2025112002023041900_bib2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025112002023041900_bib3","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"2025112002023041900_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"2025112002023041900_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"2025112002023041900_bib6","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"key":"2025112002023041900_bib7","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"2025112002023041900_bib8","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2025112002023041900_bib9","doi-asserted-by":"crossref","first-page":"e0189848","DOI":"10.1371\/journal.pone.0189848","article-title":"Safety and antitumor activity of the anti\u2013PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma","volume":"12","author":"O\u2019Neil","year":"2017","journal-title":"PLoS One"},{"key":"2025112002023041900_bib10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 Study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025112002023041900_bib11","doi-asserted-by":"crossref","first-page":"970","DOI":"10.6004\/jnccn.2015.0117","article-title":"On the verge: immunotherapy for colorectal carcinoma","volume":"13","author":"Oh","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"2025112002023041900_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2025112002023041900_bib13","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3390\/ijms18102229","article-title":"Immunogenomic classification of colorectal cancer and therapeutic implications","volume":"18","author":"Roelands","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2025112002023041900_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"2025112002023041900_bib15","doi-asserted-by":"crossref","first-page":"eaba0759","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"key":"2025112002023041900_bib16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1535-7163.MCT-21-0041","article-title":"Innate immune checkpoint inhibitors: the next breakthrough in medical oncology?","volume":"20","author":"Lentz","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2025112002023041900_bib17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","article-title":"Phagocytosis checkpoints as new targets for cancer immunotherapy","volume":"19","author":"Feng","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2025112002023041900_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","article-title":"Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis","volume":"76","author":"Weiskopf","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025112002023041900_bib19","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112002023041900_bib20","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"2025112002023041900_bib21","doi-asserted-by":"crossref","first-page":"e0201832","DOI":"10.1371\/journal.pone.0201832","article-title":"ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile","volume":"13","author":"Kauder","year":"2018","journal-title":"PLoS One"},{"key":"2025112002023041900_bib22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2164-15-190","article-title":"Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma","volume":"15","author":"Castle","year":"2014","journal-title":"BMC Genomics"},{"key":"2025112002023041900_bib23","doi-asserted-by":"crossref","first-page":"E2646","DOI":"10.1073\/pnas.1604268113","article-title":"Durable antitumor responses to CD47 blockade require adaptive immune stimulation","volume":"113","author":"Sockolosky","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112002023041900_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-020-0121-2","article-title":"The identification of a CD47-blocking \u201chotspot\u201d and design of a CD47\/PD-L1 dual-specific antibody with limited hemagglutination","volume":"5","author":"Shi","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2025112002023041900_bib25","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1038\/s41598-019-40241-1","article-title":"Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells","volume":"9","author":"Lian","year":"2019","journal-title":"Sci Rep"},{"key":"2025112002023041900_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ebiom.2019.03.018","article-title":"Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release","volume":"42","author":"Lian","year":"2019","journal-title":"EBioMedicine"},{"key":"2025112002023041900_bib27","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(21)00584-2","article-title":"Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study","volume":"22","author":"Lakhani","year":"2021","journal-title":"Lancet Oncol"},{"issue":"Suppl 4","key":"2025112002023041900_bib28","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2025.43.4_suppl.332","article-title":"Final analysis of the randomized phase 2 part of the ASPEN-06 study: a phase 2\/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric\/gastroesophageal cancer (GC)","volume":"43","author":"Shitara","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025112002023041900_bib29","volume-title":"ALX Oncology reports ASPEN-03 and ASPEN-04 phase 2 trials evaluating evorpacept with a checkpoint inhibitor for the treatment of head and neck cancers did not meet primary endpoints","author":"ALX Oncology","year":"2025"},{"key":"2025112002023041900_bib30","doi-asserted-by":"crossref","first-page":"607282","DOI":"10.3389\/fimmu.2021.607282","article-title":"Testing cancer immunotherapy in a human immune system mouse model: correlating treatment responses to human chimerism, therapeutic variables and immune cell phenotypes","volume":"12","author":"Mar\u00edn-Jim\u00e9nez","year":"2021","journal-title":"Front Immunol"},{"key":"2025112002023041900_bib31","doi-asserted-by":"crossref","first-page":"877635","DOI":"10.3389\/fonc.2022.877635","article-title":"Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models","volume":"12","author":"Lang","year":"2022","journal-title":"Front Oncol"},{"key":"2025112002023041900_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40425-019-0518-z","article-title":"Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts","volume":"7","author":"Capasso","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025112002023041900_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0022-1759(94)90012-4","article-title":"Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications","volume":"174","author":"Van Rooijen","year":"1994","journal-title":"J Immunol Methods"},{"key":"2025112002023041900_bib34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.bjc.6603240","article-title":"Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach","volume":"95","author":"Zeisberger","year":"2006","journal-title":"Br J Cancer"},{"key":"2025112002023041900_bib35","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1161\/STROKEAHA.118.024578","article-title":"Enhancement of hematoma clearance with CD47 blocking antibody in experimental intracerebral hemorrhage","volume":"50","author":"Jing","year":"2019","journal-title":"Stroke"},{"key":"2025112002023041900_bib36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.clim.2011.04.002","article-title":"Generation of hematopoietic humanized mice in the newborn BALB\/c-Rag2null Il2r\u03b3null mouse model: a multivariable optimization approach","volume":"140","author":"Lang","year":"2011","journal-title":"Clin Immunol"},{"key":"2025112002023041900_bib37","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.4049\/jimmunol.1202810","article-title":"Studies of lymphocyte reconstitution in a humanized mouse model reveal a requirement of T cells for human B cell maturation","volume":"190","author":"Lang","year":"2013","journal-title":"J Immunol"},{"key":"2025112002023041900_bib38","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1158\/0008-5472.CAN-06-3822","article-title":"Specific growth rate versus doubling time for quantitative characterization of tumor growth rate","volume":"67","author":"Mehrara","year":"2007","journal-title":"Cancer Res"},{"key":"2025112002023041900_bib39","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/02841860802616736","article-title":"Quantitative analysis of tumor growth rate and changes in tumor marker level: specific growth rate versus doubling time","volume":"48","author":"Mehrara","year":"2009","journal-title":"Acta Oncol"},{"key":"2025112002023041900_bib40","doi-asserted-by":"publisher","first-page":"54393","DOI":"10.3791\/54393","article-title":"Development and maintenance of a preclinical patient derived tumor xenograft model for the investigation of novel anti-cancer therapies","author":"Bagby","year":"2016","journal-title":"J Vis Exp"},{"key":"2025112002023041900_bib41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1\u2014update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025112002023041900_bib42","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025112002023041900_bib43","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025112002023041900_bib44","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025112002023041900_bib45","doi-asserted-by":"crossref","first-page":"eabn4118","DOI":"10.1126\/scitranslmed.abn4118","article-title":"Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu\u00e9rin","volume":"15","author":"de Jong","year":"2023","journal-title":"Sci Transl Med"},{"key":"2025112002023041900_bib46","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.celrep.2019.10.038","article-title":"Mass cytometry reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in down syndrome","volume":"29","author":"Waugh","year":"2019","journal-title":"Cell Rep"},{"key":"2025112002023041900_bib47","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.4161\/onci.21317","article-title":"Depletion of phagocytic myeloid cells triggers spontaneous T cell- and NK cell-dependent antitumor activity","volume":"1","author":"Guth","year":"2012","journal-title":"Oncoimmunology"},{"key":"2025112002023041900_bib48","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1158\/1535-7163.MCT-07-0579","article-title":"Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma","volume":"7","author":"Miselis","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"2025112002023041900_bib49","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1158\/1078-0432.CCR-09-0489","article-title":"HPV16 tumor associated macrophages suppress antitumor T cell responses","volume":"15","author":"Lepique","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2025112002023041900_bib50","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"key":"2025112002023041900_bib51","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1158\/1078-0432.CCR-24-0090","article-title":"A phase II study of potentiation of pembrolizumab with binimetinib and bevacizumab in refractory microsatellite-stable colorectal cancer","volume":"30","author":"Lentz","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025112002023041900_bib52","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat Med"},{"key":"2025112002023041900_bib53","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamaoncol.2022.7845","article-title":"Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial","volume":"9","author":"Fakih","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025112002023041900_bib54","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.23.02736","article-title":"Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study","volume":"42","author":"Kawazoe","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025112002023041900_bib55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/annonc\/mdy509","article-title":"Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge","volume":"30","author":"Parseghian","year":"2019","journal-title":"Ann Oncol"},{"key":"2025112002023041900_bib56","doi-asserted-by":"crossref","first-page":"e245635","DOI":"10.1001\/jamanetworkopen.2024.5635","article-title":"Anti-EGFR rechallenge in patients with refractory ctDNA RAS\/BRAF wt metastatic colorectal cancer: a nonrandomized controlled trial","volume":"7","author":"Ciardiello","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"Suppl 4","key":"2025112002023041900_bib57","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2020.38.4_suppl.114","article-title":"A phase Ib\/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients","volume":"38","author":"Fisher","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025112002023041900_bib58","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","article-title":"Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial","volume":"7","author":"Martinelli","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025112002023041900_bib59","doi-asserted-by":"crossref","first-page":"e2400086","DOI":"10.1200\/OA-24-00086","article-title":"Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS\/NRAS\/BRAF wild-type microsatellite stable metastatic colorectal cancer","volume":"2","author":"Somasundaram","year":"2025","journal-title":"JCO Oncol Adv"},{"key":"2025112002023041900_bib60","article-title":"Cetuximab FDA prescribing information","author":"FDA","year":"2021"},{"issue":"Suppl 15","key":"2025112002023041900_bib61","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2018.36.15_suppl.3068","article-title":"A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma","volume":"36","author":"Lakhani","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2025112002023041900_bib62","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.bbmt.2009.11.014","article-title":"Histiocytic disorders: recent insights into pathophysiology and practical guidelines","volume":"16","author":"Filipovich","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025112002023041900_bib63","doi-asserted-by":"crossref","first-page":"e05184","DOI":"10.1002\/ccr3.5184","article-title":"Secondary hemophagocytic lymphohistiocytosis due to nivolumab\/ipilimumab in a renal cell cancer patient-a case report","volume":"9","author":"Masood","year":"2021","journal-title":"Clin Case Rep"},{"key":"2025112002023041900_bib64","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1159\/000507281","article-title":"Hemophagocytic lymphohistiocytosis secondary to PD-1 and IDO inhibition in a patient with refractory glioblastoma","volume":"13","author":"Thummalapalli","year":"2020","journal-title":"Case Rep Oncol"},{"key":"2025112002023041900_bib65","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered CD47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature"},{"key":"2025112002023041900_bib66","article-title":"ENHANCE, 2, 3 studies document for posting 26 Feb","author":"Gilead Sciences","year":"2024"},{"key":"2025112002023041900_bib67","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.4049\/jimmunol.2000652","article-title":"Inflammation unrestrained by SIRP\u03b1 induces secondary hemophagocytic lymphohistiocytosis independent of IFN-\u03b3","volume":"205","author":"Kidder","year":"2020","journal-title":"J Immunol"},{"key":"2025112002023041900_bib68","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood.V118.21.522.522","article-title":"Hemophagocytic lymphohistiocytosis is caused by engulfment of hematopoietic stem cells by macrophages through stem cell-specific suppression of CD47 under influence of cytokine deregulation","volume":"118","author":"Kuriyama","year":"2011","journal-title":"Blood"},{"key":"2025112002023041900_bib69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther"},{"key":"2025112002023041900_bib70","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"Suppl 1","key":"2025112002023041900_bib71","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1182\/blood-2022-157606","article-title":"Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine and venetoclax in patients with acute myeloid leukemia (ASPEN-05): results from phase 1a dose escalation part","volume":"140","author":"Garcia-Manero","year":"2022","journal-title":"Blood"},{"key":"2025112002023041900_bib72","doi-asserted-by":"crossref","first-page":"e002855","DOI":"10.1136\/jitc-2021-002855","article-title":"Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report","volume":"9","author":"Sackstein","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025112002023041900_bib73","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/JOP.19.00160","article-title":"Cytokine release syndrome resulting from anti-programmed death-1 antibody: raising awareness among community oncologists","volume":"15","author":"Adashek","year":"2019","journal-title":"J Oncol Pract"},{"key":"2025112002023041900_bib74","doi-asserted-by":"crossref","first-page":"E10578","DOI":"10.1073\/pnas.1710877114","article-title":"Anti-SIRP\u03b1 antibody immunotherapy enhances neutrophil and macrophage antitumor activity","volume":"114","author":"Ring","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112002023041900_bib75","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1200\/JCO.23.02728","article-title":"Leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study","volume":"42","author":"Antoniotti","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025112002023041900_bib76","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/s41416-022-01876-6","article-title":"Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity","volume":"127","author":"Dongye","year":"2022","journal-title":"Br J Cancer"},{"key":"2025112002023041900_bib77","doi-asserted-by":"crossref","first-page":"706186","DOI":"10.3389\/fimmu.2021.706186","article-title":"Sargramostim (rhu GM-CSF) as cancer therapy (systematic review) and an immunomodulator. A drug before its time?","volume":"12","author":"Lazarus","year":"2021","journal-title":"Front Immunol"},{"key":"2025112002023041900_bib78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.trsl.2022.09.002","article-title":"Inflammasome signaling in colorectal cancer","volume":"252","author":"Sharma","year":"2023","journal-title":"Transl Res"},{"key":"2025112002023041900_bib79","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3390\/cancers13112695","article-title":"STING agonists as cancer therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025112002023041900_bib80","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1038\/s41467-023-39571-6","article-title":"Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat Commun"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0332\/3668557\/crc-25-0332.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/11\/2039\/3672366\/crc-25-0332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/11\/2039\/3672366\/crc-25-0332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T07:03:01Z","timestamp":1763622181000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/11\/2039\/767326\/Phase-II-Clinical-Trial-and-Preclinical-Evaluation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":80,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0332","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30664323","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664356","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664344","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664377","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664332","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664365","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664320","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664353","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664338","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664326","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664359","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664347","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664368","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664335","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664329","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664380","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664341","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664374","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664362","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664350","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664383","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30664371","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8158515","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}